Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
HYPD
Valuation N/A
HYPERION DEFI, INC.
Price$3.37
Model IV—
P/IV—
Market implies +74.8%/yr
IBIO
Valuation N/A
iBio, Inc.
Price$0.92
Model IV—
P/IV—
Market implies +50.9%/yr
vs model +2.0% · above model
IBO
Valuation N/A
IMPACT BIOMEDICAL INC.
Price$4.11
Model IV—
P/IV—
Market implies +131.4%/yr
vs model +2.0% · above model
ICCC
Deeply overvalued
IMMUCELL CORP /DE/
Price$9.75
Model IV$2.86
P/IV3.59
Premium +241%
Return to IV: -70.7%
Market implies +21.2%/yr
vs model +9.6% · above model
IDXX
Deeply overvalued
IDEXX LABORATORIES INC /DE
Price$513.14
Model IV$231.99
P/IV2.43
Premium +121%
Return to IV: -54.8%
Market implies +18.9%/yr
vs model +9.9% · above model
IDYA
Deeply overvalued
IDEAYA Biosciences, Inc.
Price$36.06
Model IV$17.32
P/IV1.70
Premium +108%
Return to IV: -52.0%
Market implies +9.7%/yr
vs model +50.0% · below model
IFRX
Valuation N/A
InflaRx N.V.
Price$1.53
Model IV—
P/IV—
Market implies +142.3%/yr
IGC
Valuation N/A
IGC Pharma, Inc.
Price$0.28
Model IV—
P/IV—
Market implies +35.2%/yr
IMCC
Valuation N/A
IM Cannabis Corp.
Price$1.72
Model IV—
P/IV—
Limited data — see page
IMDX
Valuation N/A
Insight Molecular Diagnostics Inc.
Price$3.28
Model IV—
P/IV—
Market implies +46.1%/yr
IMMP
Valuation N/A
IMMUTEP Ltd
Price$3.84
Model IV—
P/IV—
Limited data — see page
IMMX
Valuation N/A
Immix Biopharma, Inc.
Price$9.29
Model IV—
P/IV—
Limited data — see page
IMNM
Valuation N/A
Immunome Inc.
Price$19.31
Model IV—
P/IV—
Market implies +83.9%/yr
IMNN
Valuation N/A
Imunon, Inc.
Price$1.07
Model IV—
P/IV—
Market implies +7.6%/yr
vs model +15.0% · below model
IMRN
Valuation N/A
Immuron Ltd
Price$1.11
Model IV—
P/IV—
Market implies +20.3%/yr
IMRX
Valuation N/A
Immuneering Corp
Price$3.74
Model IV—
P/IV—
Market implies +90.8%/yr
vs model +15.0% · above model
IMUX
Valuation N/A
IMMUNIC, INC.
Price$7.56
Model IV—
P/IV—
Limited data — see page
INCR
Valuation N/A
Intercure Ltd.
Price$5.03
Model IV—
P/IV—
Limited data — see page
INDP
Valuation N/A
Indaptus Therapeutics, Inc.
Price$2.37
Model IV—
P/IV—
Limited data — see page
INDV
Valuation N/A
Indivior Pharmaceuticals, Inc.
Price$35.45
Model IV—
P/IV—
Market implies +88.7%/yr
INM
Deeply undervalued
InMed Pharmaceuticals Inc.
Price$1.33
Model IV$11.60
P/IV0.14
Discount 89%
Return to IV: +771.8%
Market implies -49.2%/yr
vs model +26.9% · below model
INO
Valuation N/A
INOVIO PHARMACEUTICALS, INC.
Price$1.09
Model IV—
P/IV—
Market implies +99.0%/yr
vs model +2.0% · above model
INSM
Deeply overvalued
INSMED Inc
Price$100.48
Model IV$23.52
P/IV4.55
Premium +327%
Return to IV: -76.6%
Market implies +11.4%/yr
vs model +33.9% · below model
INVA
Deeply undervalued
Innoviva, Inc.
Price$20.87
Model IV$64.08
P/IV0.33
Discount 67%
Return to IV: +207.0%
Market implies -9.3%/yr
vs model +6.5% · below model
IONS
Valuation N/A
IONIS PHARMACEUTICALS INC
Price$43.30
Model IV—
P/IV—
Market implies +6.8%/yr
vs model +3.9% · in line
IRD
Deeply overvalued
Opus Genetics, Inc.
Price$4.46
Model IV$1.51
P/IV3.21
Premium +196%
Return to IV: -66.2%
Market implies +13.4%/yr
vs model +50.0% · below model
IRON
Valuation N/A
Disc Medicine, Inc.
Price$60.77
Model IV—
P/IV—
Limited data — see page
IRWD
Undervalued
IRONWOOD PHARMACEUTICALS INC
Price$3.87
Model IV$4.82
P/IV0.74
Discount 20%
Return to IV: +24.5%
Market implies -3.3%/yr
vs model +2.0% · below model
IVA
Valuation N/A
Inventiva S.A.
Price$3.32
Model IV—
P/IV—
Limited data — see page
IXHL
Valuation N/A
Incannex Healthcare Inc.
Price$3.20
Model IV—
P/IV—
Market implies +122.6%/yr
vs model +15.0% · above model
JAGX
Overvalued
Jaguar Health, Inc.
Price$4.53
Model IV$3.76
P/IV2.37
Premium +21%
Return to IV: -17.1%
Market implies +4.1%/yr
vs model +27.7% · below model
JANX
Valuation N/A
Janux Therapeutics, Inc.
Price$18.50
Model IV—
P/IV—
Market implies +56.3%/yr
vs model +28.8% · above model
JAZZ
Deeply undervalued
Jazz Pharmaceuticals plc
Price$222.45
Model IV$483.86
P/IV0.49
Discount 54%
Return to IV: +117.5%
Market implies -2.7%/yr
vs model +8.9% · below model
JBIO
Valuation N/A
Jade Biosciences, Inc.
Price$14.15
Model IV—
P/IV—
Limited data — see page
JNJ
Overvalued
JOHNSON & JOHNSON
Price$256.48
Model IV$208.35
P/IV1.30
Premium +23%
Return to IV: -18.8%
Market implies +10.0%/yr
vs model +8.9% · in line
JUNS
Valuation N/A
JUPITER NEUROSCIENCES, INC.
Price$2.77
Model IV—
P/IV—
Market implies +133.7%/yr
vs model +15.0% · above model
KALA
Valuation N/A
KALA BIO, Inc.
Price$0.30
Model IV—
P/IV—
Market implies -1.9%/yr
vs model +15.0% · below model
KALV
Valuation N/A
KalVista Pharmaceuticals, Inc.
Price$27.00
Model IV—
P/IV—
Market implies +34.7%/yr
vs model +15.0% · above model
KAPA
Valuation N/A
Kairos Pharma, LTD.
Price$0.96
Model IV—
P/IV—
Limited data — see page
KLRA
Valuation N/A
Kailera Therapeutics, Inc.
Price$10.00
Model IV—
P/IV—
Limited data — see page
KMDA
Deeply overvalued
KAMADA LTD
Price$7.78
Model IV$5.59
P/IV1.57
Premium +39%
Return to IV: -28.1%
Market implies +12.5%/yr
vs model +11.5% · in line
KNSA
Deeply overvalued
Kiniksa Pharmaceuticals International, plc
Price$78.75
Model IV$48.57
P/IV1.00
Premium +62%
Return to IV: -38.3%
Market implies +13.8%/yr
vs model +10.0% · above model
KPRX
Valuation N/A
KIORA PHARMACEUTICALS INC
Price$2.53
Model IV—
P/IV—
Market implies -4.7%/yr
vs model +15.0% · below model
KPTI
Valuation N/A
Karyopharm Therapeutics Inc.
Price$0.60
Model IV—
P/IV—
Limited data — see page
KROS
Deeply undervalued
Keros Therapeutics, Inc.
Price$11.64
Model IV$34.65
P/IV0.32
Discount 66%
Return to IV: +197.7%
Market implies -9.8%/yr
vs model +10.0% · below model
KRRO
Valuation N/A
Korro Bio, Inc.
Price$10.58
Model IV—
P/IV—
Market implies +72.9%/yr
KTTA
Valuation N/A
Pasithea Therapeutics Corp.
Price$0.44
Model IV—
P/IV—
Market implies +19.9%/yr
KTTAW
Valuation N/A
Pasithea Therapeutics Corp.
Price$0.00
Model IV—
P/IV—
Market implies -24.4%/yr
KURA
Valuation N/A
Kura Oncology, Inc.
Price$10.52
Model IV—
P/IV—
Market implies +31.2%/yr
KYNB
Valuation N/A
KYNTRA BIO, INC.
Price$5.96
Model IV—
P/IV—
Market implies +37.8%/yr
vs model +2.0% · above model
KZIA
Valuation N/A
KAZIA THERAPEUTICS LTD
Price$8.82
Model IV—
P/IV—
Market implies +129.1%/yr
LABT
Valuation N/A
Lakewood-Amedex Biotherapeutics Inc.
Price$0.79
Model IV—
P/IV—
Limited data — see page
LBRX
Valuation N/A
LB PHARMACEUTICALS INC
Price$34.61
Model IV—
P/IV—
Limited data — see page
LEGN
Deeply undervalued
Legend Biotech Corp
Price$18.71
Model IV$50.42
P/IV0.37
Discount 63%
Return to IV: +169.5%
Market implies -16.9%/yr
vs model +50.0% · below model
LEXX
Valuation N/A
Lexaria Bioscience Corp.
Price$3.20
Model IV—
P/IV—
Market implies +56.2%/yr
LFCR
Deeply overvalued
LIFECORE BIOMEDICAL, INC. DE
Price$6.43
Model IV$2.86
P/IV1.75
Premium +124%
Return to IV: -55.5%
Market implies +7.9%/yr
vs model +6.3% · in line
LFVN
Overvalued
Lifevantage Corp
Price$5.99
Model IV$4.63
P/IV1.34
Premium +29%
Return to IV: -22.7%
Market implies +6.4%/yr
vs model +6.1% · in line
LGND
Valuation N/A
LIGAND PHARMACEUTICALS INC
Price$295.00
Model IV—
P/IV—
Market implies +36.7%/yr
vs model +2.6% · above model
LGVN
Valuation N/A
Longeveron Inc.
Price$2.37
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +14.1% · above model
LITS
Valuation N/A
Lite Strategy, Inc.
Price$1.22
Model IV—
P/IV—
Market implies -21.0%/yr
vs model +15.0% · below model